MENLO PARK, Calif.– Nuvig Therapeutics, Inc., a privately held biotechnology company developing immunomodulatory therapies for inflammatory autoimmune diseases, announced the appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and member of the Board of Directors, and James Mackay, Ph.D., as Independent Board Chair.
“David’s systematic approach and track record in successfully guiding biotechnology companies through critical growth stages, alongside his extensive knowledge in life sciences, finance, and business development, position him to lead Nuvig through its next phase of development,” said Pamela Conley, Ph.D., Founder and Chief Scientific Officer of Nuvig. “We are equally pleased to announce that James Mackay now serves as Independent Chair of the Board. Together, their leadership will be invaluable as we advance NVG-2089 in multiple Phase 2 clinical trials and broaden the reach of our BESTech platform into additional autoimmune indications.”
Dr. Woodhouse said he is eager to lead the company through its next chapter. “With NVG-2089, we have the potential to deliver a potent, patient-friendly alternative to IVIg that is scalable, consistent, and precisely engineered,” he said. “I look forward to working closely with Pam, James, the Board, and our talented team to bring this important therapy to patients and to more broadly leverage the BESTech platform’s capabilities to advance multiple new treatments for autoimmune and inflammatory diseases.”
Woodhouse brings more than 23 years of experience across science, strategy, finance, and capital development. Most recently, he was Chief Executive Officer and director of NGM Biopharmaceuticals, Inc., where he led the company through multiple clinical milestones and strategic partnerships. He previously served as NGM’s Chief Financial Officer for more than three years and earlier was Managing Director and co-head of biotechnology investment banking at Goldman Sachs. His career also includes roles at Dynavax Technologies and Amgen. He holds a Ph.D. in molecular pharmacology from Stanford University, an M.B.A. from the Tuck School of Business at Dartmouth, and a B.A. in pharmacology from the University of California, Santa Barbara.
Dr. Mackay is a seasoned biotechnology executive with experience in drug development, corporate strategy, and building high-performing teams. He is currently CEO of Kateran Consulting and has previously served as CEO of Ardea Bioscience and Aristea Therapeutics, in addition to holding senior leadership positions at AstraZeneca.
